Pakistan announced the effectiveness rate of the single-dose Covid-19 vaccine developed by the Chinese company CanSinoBIO as 74,8 percent. Developed by a team led by Chen Wei, a researcher at the Beijing-based Academy of Military Medical Sciences, the vaccine is the first single-dose vaccine developed by Chinese companies.
Private Health Assistant of Pakistani Prime Minister Dr. Faysal Sultan said in a statement yesterday that CanSinoBIO's vaccine has an effect of 74,8 percent in symptomatic cases and 100 percent in preventing severe disease, according to the results of the third stage clinical trials in Pakistan.
According to the information provided by the World Health Organization (WHO), CanSinoBIO's Ad5-nCov vaccine was the first vaccine in the world to go to second stage clinical trials. Ad5-nCov is also the second single-dose vaccine with the vaccine developed by Johnson & Johnson, with the results of the third stage clinical trials disclosed. CanSinoBIO announced on February 1 that more than 3 people were vaccinated in Phase-40 trials of the vaccine in five countries, including Mexico, Russia, Pakistan, Argentina and Chile.
Source: China International Radio